phase readout
saveNCT07298408: Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
community read0 votes
Sponsor: Florida A&M University. Phase: PHASE1. Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
view source ↗Data sources
last refreshed 53m ago
Found something off?
same company · ±60 days · 6
- earningsJazz Pharmaceuticals plc earningsAug 4, 2026
- earningsJazz Pharmaceuticals plc earningsAug 3, 2026
- earningsJazz Pharmaceuticals plc earningsMay 5, 2026
- phase 2 initiationdurvalumab: Jazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)Apr 25, 2026
- approvallurbinectedin: ZEPZELCA (LURBINECTEDIN) — FDA approvalFeb 27, 2026
- approvallurbinectedin: ZEPZELCA (LURBINECTEDIN) — FDA approvalOct 2, 2025
related news · 8
- statHow Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
- biopharma diveAn orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
- fiercebiotechIambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
- fiercebiotechRoche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
- biospaceBeyond China: Five other overseas destinations for biopharma dollars
- endpointsUK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
- fiercebiotechRoche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drug
- biospaceJazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
comments(0)
5-min edit window · permanent after that